Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone484-324-7933
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.09 million
Profitability
Miscellaneous
Employees169
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions
What is Aclaris Therapeutics' stock symbol?
Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."
How were Aclaris Therapeutics' earnings last quarter?
Aclaris Therapeutics Inc (NASDAQ:ACRS) released its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.72) earnings per share for the quarter, topping analysts' consensus estimates of ($0.77) by $0.05. The biotechnology company had revenue of $5.87 million for the quarter, compared to the consensus estimate of $5.77 million. Aclaris Therapeutics had a negative return on equity of 81.40% and a negative net margin of 979.65%. View Aclaris Therapeutics' Earnings History.
When is Aclaris Therapeutics' next earnings date?
What price target have analysts set for ACRS?
5 brokerages have issued 12 month price objectives for Aclaris Therapeutics' shares. Their predictions range from $5.00 to $13.00. On average, they anticipate Aclaris Therapeutics' share price to reach $9.00 in the next year. This suggests a possible upside of 480.6% from the stock's current price. View Analyst Price Targets for Aclaris Therapeutics.
What is the consensus analysts' recommendation for Aclaris Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aclaris Therapeutics.
Has Aclaris Therapeutics been receiving favorable news coverage?
Media headlines about ACRS stock have been trending very positive recently, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aclaris Therapeutics earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for Aclaris Therapeutics.
Are investors shorting Aclaris Therapeutics?
Aclaris Therapeutics saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 2,630,000 shares, a drop of 11.4% from the August 30th total of 2,970,000 shares. Based on an average daily volume of 1,710,000 shares, the days-to-cover ratio is presently 1.5 days. Currently, 7.5% of the company's shares are sold short. View Aclaris Therapeutics' Current Options Chain.
Who are some of Aclaris Therapeutics' key competitors?
Some companies that are related to Aclaris Therapeutics include Forty Seven (FTSV), Cyclerion Therapeutics (CYCN), resTORbio (TORC), Puma Biotechnology (PBYI), BIOFRONTERA AG/ADR (BFRA), Osmotica Pharmaceuticals (OSMT), Provention Bio (PRVB), MannKind (MNKD), Seres Therapeutics (MCRB), Xeris Pharmaceuticals (XERS), Evofem Biosciences (EVFM), Albireo Pharma (ALBO), Xenon Pharmaceuticals (XENE), Applied Therapeutics (APLT) and Aeglea Bio Therapeutics (AGLE).
What other stocks do shareholders of Aclaris Therapeutics own?
Who are Aclaris Therapeutics' key executives?
Aclaris Therapeutics' management team includes the folowing people:
- Dr. Neal S. Walker D.O., Co-Founder, CEO, Pres & Director (Age 49)
- Mr. Christopher V. Powala, Co-Founder and Chief Regulatory & Devel. Officer (Age 60)
- Dr. Stuart D. Shanler, Co-Founder & Chief Scientific Officer (Age 58)
- Mr. Frank Ruffo, Co-Founder & CFO (Age 53)
- Ms. Kamil Ali-Jackson J.D., Co-Founder, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 60)
How do I buy shares of Aclaris Therapeutics?
Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aclaris Therapeutics' stock price today?
One share of ACRS stock can currently be purchased for approximately $1.55.
How big of a company is Aclaris Therapeutics?
Aclaris Therapeutics has a market capitalization of $64.12 million and generates $10.09 million in revenue each year. The biotechnology company earns $-132,740,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe.View Additional Information About Aclaris Therapeutics.
What is Aclaris Therapeutics' official website?
How can I contact Aclaris Therapeutics?
Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]
MarketBeat Community Rating for Aclaris Therapeutics (NASDAQ ACRS)
MarketBeat's community ratings are surveys of what our community members think about Aclaris Therapeutics and other stocks. Vote "Outperform" if you believe ACRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
